Nesina (alogliptin) Disease Interactions
There are 3 disease interactions with Nesina (alogliptin):
Dpp-4 Inhibitors (Includes Nesina) ↔ Pancreatitis
Severe Potential Hazard, Low plausibility
Applies to: Pancreatitis
There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.
Alogliptin (Includes Nesina) ↔ Liver Disease
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
There have been postmarketing reports of hepatic failure (fatal and non-fatal) in patients taking alogliptin. Treatment should be started with caution in patients with preexisting liver disease. It is recommended to assess the liver function of the patient before starting therapy. If liver test abnormalities worsen without explanation during treatment, therapy should be discontinued and the cause of the abnormalities should be studied.
Dpp-4 (Includes Nesina) ↔ Renal Dysfunction
Moderate Potential Hazard, High plausibility
Applies to: Renal Dysfunction
It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors. Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment. Linagliptin will not require a dose adjustment per manufacturer's information. Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses. However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.
Nesina (alogliptin) drug Interactions
There are 637 drug interactions with Nesina (alogliptin)
Nesina (alogliptin) alcohol/food Interactions
There is 1 alcohol/food interaction with Nesina (alogliptin)
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
|Major||Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderate||Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minor||Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.